363 related articles for article (PubMed ID: 30296870)
21. Reversal agents for non-vitamin K antagonist oral anticoagulants.
Levy JH; Douketis J; Weitz JI
Nat Rev Cardiol; 2018 May; 15(5):273-281. PubMed ID: 29345686
[TBL] [Abstract][Full Text] [Related]
22. Preclinical safety and efficacy of andexanet alfa in animal models.
Lu G; Hollenbach SJ; Baker DC; Tan S; Hutchaleelaha A; Curnutte JT; Conley PB
J Thromb Haemost; 2017 Sep; 15(9):1747-1756. PubMed ID: 28682477
[TBL] [Abstract][Full Text] [Related]
23. Outcomes Associated With 4-Factor Prothrombin Complex Concentrate Administration to Reverse Oral Factor Xa Inhibitors in Bleeding Patients.
Highsmith EA; Morton C; Varnado S; Donahue KR; Sulhan S; Lista A
J Clin Pharmacol; 2021 May; 61(5):598-605. PubMed ID: 33094836
[TBL] [Abstract][Full Text] [Related]
24. Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants.
Gómez-Outes A; Alcubilla P; Calvo-Rojas G; Terleira-Fernández AI; Suárez-Gea ML; Lecumberri R; Vargas-Castrillón E
J Am Coll Cardiol; 2021 Jun; 77(24):2987-3001. PubMed ID: 34140101
[TBL] [Abstract][Full Text] [Related]
25. Andexanet Alfa: What We Have Learned from Clinical Trials and Real-World Data.
Frol S; Oblak JP; Šabovič M; Kermer P
CNS Drugs; 2024 Mar; 38(3):163-168. PubMed ID: 38396232
[TBL] [Abstract][Full Text] [Related]
26. Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding.
Stevens VM; Trujillo TC; Kiser TH; MacLaren R; Reynolds PM; Mueller SW
Clin Appl Thromb Hemost; 2021; 27():10760296211039020. PubMed ID: 34541920
[TBL] [Abstract][Full Text] [Related]
27. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity: Prespecified Subgroup Analysis of the ANNEXA-4 Study in Japan.
Toyoda K; Arakawa S; Ezura M; Kobayashi R; Tanaka Y; Hasegawa S; Yamashiro S; Komatsu Y; Terasawa Y; Masuno T; Kobayashi H; Oikawa S; Yasaka M
J Atheroscler Thromb; 2024 Mar; 31(3):201-213. PubMed ID: 37635060
[TBL] [Abstract][Full Text] [Related]
28. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study.
Smith MN; Deloney L; Carter C; Weant KA; Eriksson EA
J Thromb Thrombolysis; 2019 Aug; 48(2):250-255. PubMed ID: 30941571
[TBL] [Abstract][Full Text] [Related]
29. Deterioration free discharge comparison of andexanet-alfa and prothrombin complex concentrates (PCC) for reversal of factor Xa inhibitor associated bleeds.
Keinath JJ; Lekura J; Hauser CD; Bajwa MK; Bloome ME; Kalus JS; Jones MC
J Thromb Thrombolysis; 2023 Aug; 56(2):315-322. PubMed ID: 37289371
[TBL] [Abstract][Full Text] [Related]
30. [Andexanet alfa (ONDEXXYA
Yajima T; Higashimori M; Takata C; Sasabe T
Nihon Yakurigaku Zasshi; 2023; 158(1):89-100. PubMed ID: 36596498
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of oral factor Xa inhibitor-associated extracranial bleeding reversal with andexanet alfa.
Nederpelt CJ; Naar L; Sylvester KW; Barra ME; Roberts RJ; Velmahos GC; Kaafarani HMA; Rosenthal MG; King DR
J Thromb Haemost; 2020 Oct; 18(10):2532-2541. PubMed ID: 32738161
[TBL] [Abstract][Full Text] [Related]
32. Retrospective review of Andexanet Alfa versus 4-Factor Prothrombin Complex Concentrate for reversal of DOAC-Associated Intracranial Hemorrhage.
Troyer C; Nguyen W; Xie A; Wimer D
J Thromb Thrombolysis; 2023 Jan; 55(1):149-155. PubMed ID: 36355324
[TBL] [Abstract][Full Text] [Related]
33. Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures.
Bradshaw PG; Keegan SP; Droege ME; Dykes NJH; Ernst NE; Foertsch MJ; Makley AT; Mueller EW; Philpott CD; Srinivasan V; Winter JB; Goodman MD; Droege CA
Pharmacotherapy; 2022 Oct; 42(10):780-791. PubMed ID: 36073083
[TBL] [Abstract][Full Text] [Related]
34. How can we reverse bleeding in patients on direct oral anticoagulants?
Crowther M; Cuker A
Kardiol Pol; 2019; 77(1):3-11. PubMed ID: 30338501
[TBL] [Abstract][Full Text] [Related]
35. Preclinical and clinical data for factor Xa and "universal" reversal agents.
Milling TJ; Kaatz S
Am J Emerg Med; 2016 Nov; 34(11S):39-45. PubMed ID: 27697443
[TBL] [Abstract][Full Text] [Related]
36. Comparative analysis of andexanet alfa and prothrombin complex concentrate in reversing anticoagulation by rivaroxaban ex vivo.
Rayatdoost F; Deventer K; Rossaint R; Schöchl H; Grottke O
Br J Anaesth; 2024 Feb; 132(2):251-259. PubMed ID: 38030550
[TBL] [Abstract][Full Text] [Related]
37. Management of bleeding in patients receiving non-vitamin K antagonists.
Balla S; Koerber S; Flaker G
Postgrad Med J; 2017 Apr; 93(1098):221-225. PubMed ID: 27986971
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of action and clinical use of specific reversal agents for non-vitamin K antagonist oral anticoagulants.
Andresen K; Atar D; Gjertsen E; Ghanima W; Roseth S; Johansen OE
Scand Cardiovasc J; 2018 Jun; 52(3):156-162. PubMed ID: 29569500
[TBL] [Abstract][Full Text] [Related]
39. Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care.
Huttner HB; Gerner ST; Kuramatsu JB; Connolly SJ; Beyer-Westendorf J; Demchuk AM; Middeldorp S; Zotova E; Altevers J; Andersohn F; Christoph MJ; Yue P; Stross L; Schwab S
Stroke; 2022 Feb; 53(2):532-543. PubMed ID: 34645283
[TBL] [Abstract][Full Text] [Related]
40. Reversal of direct oral anticoagulants.
Almegren M
Vasc Health Risk Manag; 2017; 13():287-292. PubMed ID: 28769570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]